{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MPN+%28Myeloproliferative+Neoplasms%29&page=3", "query": { "condition": "MPN (Myeloproliferative Neoplasms)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 78, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MPN+%28Myeloproliferative+Neoplasms%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MPN+%28Myeloproliferative+Neoplasms%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T14:50:16.417Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03072043", "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Myeloproliferative Neoplasm", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "APR-246", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2017-05-18", "completion_date": "2021-12-08", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03072043" }, { "nct_id": "NCT01351545", "title": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancies", "Inherited Disorders of Metabolism", "Inherited Abnormalities of Platelets", "Histiocytic Disorders", "Acute Myelogenous Leukemia (AML or ANLL)", "Acute Lymphoblastic Leukemia (ALL)", "Other Acute Leukemia", "Chronic Myelogenous Leukemia (CML)", "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases", "Other Leukemia", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma", "Multiple Myeloma/ Plasma Cell Disorder (PCD)", "Inherited Abnormalities of Erythrocyte Differentiation or Function", "Disorders of the Immune System", "Autoimmune Diseases", "Severe Aplastic Anemia" ], "interventions": [ { "name": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 99999, "start_date": "2011-10", "completion_date": "2041-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 142, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351545" }, { "nct_id": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Solid Tumor" ], "interventions": [ { "name": "PF-0791800 (TTI-621)", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Rituximab", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2016-01-28", "completion_date": "2022-11-23", "has_results": true, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 47, "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663518" }, { "nct_id": "NCT04041050", "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-11-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 12, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041050" }, { "nct_id": "NCT05549661", "title": "Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Chronic Myelomonocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified", "Recurrent Atypical Chronic Myeloid Leukemia", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Myelodysplastic/Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Onvansertib", "type": "DRUG" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-04-04", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05549661" }, { "nct_id": "NCT02587598", "title": "Study of INCB053914 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB053914", "type": "DRUG" }, { "name": "I-DAC (Intermediate dose cytarabine)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2015-12-29", "completion_date": "2020-08-11", "has_results": true, "last_update_posted_date": "2021-12-08", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 19, "location_summary": "Tucson, Arizona • Sacramento, California • Santa Monica, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587598" }, { "nct_id": "NCT04996875", "title": "(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Systemic Mastocytosis (AdvSM)", "SM With an Associated Hematologic Neoplasm (SM-AHN)", "Mast Cell Leukemia (MCL)", "Aggressive Systemic Mastocytosis (ASM)" ], "interventions": [ { "name": "bezuclastinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2021-11-09", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996875" }, { "nct_id": "NCT05005182", "title": "Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified", "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-02-20", "completion_date": "2023-06-17", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005182" }, { "nct_id": "NCT07349134", "title": "WELL-MPN: A Digital Lifestyle App for Patients With MPNs", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myeloproliferative Neoplasms (MPNs)" ], "interventions": [ { "name": "WELL-MPN Digital App", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2027-01", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07349134" }, { "nct_id": "NCT03613532", "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)", "MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)", "Hematopoietic Stem Cell Transplant" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Decitabine/cedazuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacqueline Garcia, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2018-10-24", "completion_date": "2030-03-05", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-07T14:50:16.417Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03613532" } ] }